Osurnia™—a new treatment for otitis externa


Osurnia, a topical ear treatment, offers veterinarians an “easily administered alternative to traditional otitis externa treatments”, according to its manufacturer, Elanco.

Osurnia consists of a gel formulation that requires only two doses per ear, applied one week apart, which provides optimal distribution of the treatment throughout the ear canal with less mess and up to 45 days of efficacy1,2. Osurnia is easy to use and is administered in a pre-measured, single-dose tube ensuring the right dose every time.


1. Elanco Study Number GSO-12-001. Data on file. 

2. Elanco Study Number INT-11-011. Data on file.

OsurniaTM (florfenicol/terbinafine/betamethasone acetate) and Elanco are trademarks owned or licensed to Eli Lilly and Company, its subsidiaries or affiliates. © 2017 Elanco, a division of Eli Lilly and Company Ltd. AUCACOSU00026a


Please enter your comment!
Please enter your name here